At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pharmacokinetic-pharmacodynamic Analysis of Reversal of Rocuronium-induced Neuromuscular Blockade by Sugammadex in Children
In Brief
A Phase 2 clinical trial evaluating Sugammadex Injection 2mg/kg, Sugammadex Injection 4mg/kg, and 2 other interventions for Anesthesia, General and Neuromuscular Blockade. Completed, enrolled 40 participants across 1 site.
Detailed Summary
This study administers sugammadex sodium to pediatric patients under general anesthesia with rocuronium. Pharmacokinetic and pharmacodynamic analysis are performed based on plasma concentration of sugammadex sodium and monitoring of neuromuscular blockade.
Study Details
Timeline
Interventions
Intravenous injection of 2mg/kg of sugammadex sodium 15 minutes after rocuronium administration
Intravenous injection of 4mg/kg of sugammadex sodium 15 minutes after rocuronium administration
Intravenous injection of 8mg/kg of sugammadex sodium 15 minutes after rocuronium administration
Intravenous injection of 0.02mg/kg of atropine and 0.03mg/kg of neostigmine